Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00581789 · ClinicalTrials.gov registry record · Phase 1
Erlotinib and Sunitinib in NSCLC
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00581789 is a Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 11 participants.
The verdict
NCT00581789, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
* To determine the safety and maximally tolerated dose of sunitinib plus erlotinib in patients with non-small cell lung cancer (NSCLC). * To determine response to sunitinib plus erlotinib in patients with non-small cell lung cancer.
Interventions
- DRUG erlotinib, sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-08 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00581789
The ClinicalTrials.gov registry entry for NCT00581789 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which erlotinib, sunitinib is the first listed.
NCT00581789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00581789 about?
NCT00581789 is a clinical study titled "Erlotinib and Sunitinib in NSCLC". * To determine the safety and maximally tolerated dose of sunitinib plus erlotinib in patients with non-small cell lung cancer (NSCLC). * To determine response to sunitinib plus erlotinib in patients with non-small cell lung cancer.
What is the current status of trial NCT00581789?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2007-08. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00581789?
The interventions under investigation include: erlotinib, sunitinib (DRUG).
Who is sponsoring clinical trial NCT00581789?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.